Nichi-Iko Takes Share Of Korean Biosimilar Firm Aprogen, Gains Japanese Rights For Remicade And Herceptin Generics
This article was originally published in The Pink Sheet Daily
Aprogen - founded in 2000 and an affiliate of Korean firm Schnell Biopharmaceuticals - is currently in talks with pharmas in Europe and Central and South America for biosimilar licensing deals.
You may also be interested in...
Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products
SEOUL - South Korean biotech firm Celltrion said it has successfully completed Phase I clinical trials on its biosimilar versions of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade(infliximab)
Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan
In a recurring feature, PharmAsia News monitors major earnings calls to report on new trends in emerging market strategies.